 LOS ANGELES--BUSINESS WIRE--- CDXC collaboration--ChromaDex Corp. NASDAQ: CDXC today announced a new research initiative with the Citrin Foundation of Singapore to study the effects of Niagen nicotinamide riboside NR and citrin deficiency, a rare genetic condition. In collaboration with the ChromaDex External Research Program CERPTM and leading research institutions, the Citrin Foundation will fund a series of preclinical and clinical studies to explore the potential impact of increased NAD levels on patien 